Neurológia pre prax 4/2023
Novel treatment for myasthenia gravis
Myasthenia gravis (MG) is a rare autoimmune disease characterized by muscle weakness and fatigue. In addition to the currently used non-specifically acting immunomodulating treatment, new specific immunotherapeutics has significantly expanded in recent years. This includes inhibitors of the C5 complement protein, blockers of the neonatal Fc receptor, drugs that cause depletion of B and T lymphocytes and others. The great advantage of all these medicinal products is a faster effect and a significantly lower incidence of side effects. A significant limitation of their use in normal clinical practice may be their expected high price.
Keywords: generalized myasthenia gravis, blockers of neonatal Fc receptors, complement inhibitors, B cell depleting agents, genetically modifying T cells
